Paolo Tarantino shared a post on X:
“Among the many great ESMO24 posters there was an interesting biomarker study of DB04.
2 notable findings:
-HER2 mRNA seems to predict T.
-DXd PFS better than IHC.
Confirms that we need quantitative assays. -T-DXd had shorter PFS in pts with BRCA mutations. Surprising. Prior PARPi?”
Source: Paolo Tarantino/X
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.